PT  - JOURNAL ARTICLE
AU  - Selewski, D.T.
AU  - Shah, G.V.
AU  - Segal, B.M.
AU  - Rajdev, P.A.
AU  - Mukherji, S.K.
TI  - Natalizumab (Tysabri)
AID  - 10.3174/ajnr.A2226
DP  - 2010 Oct 01
TA  - American Journal of Neuroradiology
PG  - 1588--1590
VI  - 31
IP  - 9
4099  - http://www.ajnr.org/content/31/9/1588.short
4100  - http://www.ajnr.org/content/31/9/1588.full
SO  - Am. J. Neuroradiol.2010 Oct 01; 31
AB  - SUMMARY: Natalizumab is a humanized IgG4κ monoclonal antibody that is a selective adhesion molecule inhibitor, which prevents adhesion of leukocytes to endothelial cells. It is the first monoclonal antibody approved by the FDA for the treatment of relapsing-remitting MS. This article will review the mechanism of action and clinical role of this agent. FDAUS Food and Drug AdministrationFLAIRfluid-attenuated inversion recoveryFSEfast spin-echoIgGimmunoglobulin GMAdCAM-1mucosal adressin cell adhesion moleculeMSmultiple sclerosisPMLprogressive multifocal leukoencephalopathyTOUCHTysabri Outreach Unified Commitment to HealthVCAM -1vascular cell adhesion molecule-1